ATHE

Alterity Therapeutics Ltd ADR

2.62

Oct 16 • 3:59 PM ET -0.10 (-3.68%)

2.62

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Australia Micro NASD

Peers: ACRV ANIX ATYR COYA CYPH INO LONA NRXS NRXP KALA

Scroll to Statements

Index	-
Market Cap	50.04M
Enterprise Value	24.32M
Income	-15.99M
Sales	0.00M
Book/sh	1.63
Cash/sh	1.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Sep 05, 2002

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.60
P/C	1.94
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.52
Current Ratio	14.52
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.90
EPS next Y	-0.34
EPS next Q	-
EPS this Y	-225.68%
EPS next Y	-30.09%
EPS next 5Y	-
EPS past 3/5Y	80.11% 66.10%
Sales past 3/5Y	- -
EPS Y/Y TTM	96.65%
Sales Y/Y TTM	-
EPS Q/Q	-155.28%
Sales Q/Q	-
Earnings	Aug 28 BMO
EPS/Sales Surpr.	55.99% -87.55%

Insider Own	4.67%
Insider Trans	5.64%
Inst Own	2.06%
Inst Trans	59.77%
ROA	-51.53%
ROE	-55.71%
ROIC	-53.83%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.00%
SMA50	-34.18%
SMA200	-35.04%
Trades

Shs Outstand	19.10M
Shs Float	18.20M
Short Float	0.14%
Short Ratio	1.46
Short Interest	0.03M
52W High	5.89 -55.53%
52W Low	2.62 0.00%
Volatility	14.24% 9.16%
ATR (14)	0.31
RSI (14)	25.19
Beta	0.30
Rel Volume	3.13
Avg Volume	17.85K
Volume	55,910

Perf Week	-15.89%
Perf Month	-30.13%
Perf Quarter	-44.73%
Perf Half Y	-41.39%
Perf YTD	-14.94%
Perf Year	-45.76%
Perf 3Y	14.41%
Perf 5Y	-80.00%
Perf 10Y	-91.76%
Recom	1.00
Target Price	18.43
Prev Close	2.72
Price	2.62
Change %	-3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-26	Initiated	Craig Hallum	Buy	$12
Jun-16-26	Resumed	Ladenburg Thalmann	Buy	$10
Feb-03-25	Downgrade	The Benchmark Company	Speculative Buy → Hold
Dec-12-24	Initiated	Maxim Group	Buy	$8

Oct-09-26 07:05AM	Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference (GlobeNewswire)
Oct-05-26 07:05AM	Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) -6.67%
Sep-03-26 07:05AM	Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 (GlobeNewswire)
Aug-12-26 07:05AM	Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 (GlobeNewswire)
Aug-06-26 07:25AM	Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference (GlobeNewswire)
07:25AM	Loading…
Jul-30-26 07:25AM	Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
Jul-21-26 07:25AM	Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 (GlobeNewswire) +5.06%
Jul-07-26 07:05AM	Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy (GlobeNewswire) -6.79%
Jun-09-26 07:05AM	Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy (GlobeNewswire) +9.44%
May-19-26 07:25AM	Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy (GlobeNewswire)
May-11-26 07:25AM	Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy (GlobeNewswire)
May-07-26 07:25AM	Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 (GlobeNewswire)
Apr-30-26 07:25AM	Alterity Therapeutics Releases Appendix 4C - Q3 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
Apr-27-26 07:25AM	Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy (GlobeNewswire)
Apr-22-26 07:25AM	Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology (GlobeNewswire) -6.49%
07:25AM	Loading…
Apr-17-26 07:25AM	Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors (GlobeNewswire) +12.59%
Apr-16-26 07:25AM	Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting (GlobeNewswire) +6.43%
Apr-15-26 07:25AM	Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy (GlobeNewswire)
Mar-30-26 07:25AM	Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program (GlobeNewswire) +12.97%
Mar-09-26 07:25AM	Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit (GlobeNewswire)
Mar-04-26 07:25AM	Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor (GlobeNewswire)
Mar-02-26 07:25AM	Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments (GlobeNewswire)
Jan-30-26 07:25AM	Alterity Therapeutics: Appendix 4C - Q2 FY26 Quarterly Cash Flow Report & Corporate Update (GlobeNewswire)
Jan-21-26 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 (GlobeNewswire)
Nov-12-25 07:25AM	Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference (GlobeNewswire)
Nov-10-25 07:25AM	Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System (GlobeNewswire) +8.27%
Oct-31-25 07:25AM	Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report (GlobeNewswire) -8.48%
Oct-09-25 07:25AM	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Oct-02-25 07:35AM	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) +6.08%
Sep-30-25 03:01PM	Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 (Insider Monkey)
07:25AM	Loading…
Sep-15-25 07:25AM	Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting (GlobeNewswire)
Sep-08-25 07:35AM	Alterity Therapeutics Raises A$20.0 million in Strategic Placement (GlobeNewswire)
Sep-02-25 07:25AM	Alterity Therapeutics to Present at the Biotech Showcase (GlobeNewswire)
Aug-17-25 01:54AM	Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy (Insider Monkey)
Jul-30-25 07:25AM	Appendix 4C - Q4 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Jul-28-25 07:25AM	Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy (GlobeNewswire) -14.81%
Jul-24-25 07:25AM	Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study (GlobeNewswire) +13.76%
Jun-23-25 07:25AM	Alterity Therapeutics to Provide Corporate Update in Fireside Chat (GlobeNewswire)
May-12-25 07:35AM	Alterity Therapeutics Prominently Featured at the International MSA Congress (GlobeNewswire) -8.54%
May-07-25 08:16AM	Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress (GlobeNewswire)
May-05-25 07:35AM	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy (GlobeNewswire) +26.45%
Apr-30-25 07:35AM	Appendix 4C Q3 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Apr-28-25 07:35AM	Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium (GlobeNewswire)
Apr-10-25 07:35AM	Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Apr-03-25 07:35AM	Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting (GlobeNewswire) -5.39%
Mar-27-25 07:25AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy (GlobeNewswire)
Feb-10-25 07:25AM	Alterity Therapeutics Raises A$40.0 million in Placement (GlobeNewswire) +8.71%
Jan-30-25 07:35AM	Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy (GlobeNewswire) +57.04%
Jan-24-25 07:35AM	Appendix 4C Q2 FY25 Quarterly Cash Flow Report (GlobeNewswire) -11.98%
Jan-10-25 07:35AM	Alterity CEO says filled with optimism for 2025 (TipRanks)
Jan-09-25 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-04-24 07:35AM	Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy (GlobeNewswire) +17.49%
Nov-19-24 07:25AM	Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary (GlobeNewswire)
Nov-12-24 07:35AM	Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium (GlobeNewswire)
Nov-06-24 07:35AM	Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 (GlobeNewswire)
Oct-31-24 07:35AM	Appendix 4C Q1 FY25 Quarterly Cash Flow Report (GlobeNewswire)
Oct-14-24 07:35AM	Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 (GlobeNewswire)
Oct-11-24 07:35AM	Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting (GlobeNewswire)
Oct-02-24 07:35AM	Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Sep-30-24 07:35AM	Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer (GlobeNewswire)
Sep-23-24 07:35AM	Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire)
Jul-31-24 07:35AM	Appendix 4C Q4 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Jul-24-24 07:35AM	Alterity Therapeutics to Present at MST Financial Webinar (GlobeNewswire)
Jul-18-24 11:01AM	Alterity (ATHE) Up on Interim Data From Advance MSA Study (Zacks) -11.01%
Jul-17-24 07:35AM	Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.34%
Jun-12-24 07:22PM	Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar (GlobeNewswire)
May-29-24 07:21PM	Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study (GlobeNewswire)
May-08-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review (GlobeNewswire)
Apr-30-24 07:25AM	Appendix 4C Q3 FY24 Quarterly Cash Flow Report (GlobeNewswire)
Apr-29-24 07:25AM	Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia (GlobeNewswire) -12.55%
Apr-17-24 07:25AM	Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 07:25AM	Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 (GlobeNewswire) +14.66%
Mar-26-24 10:25AM	Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund (GlobeNewswire) +5.26%
Feb-20-24 10:25AM	Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Feb-06-24 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review (GlobeNewswire)
Jan-29-24 07:24AM	Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week (GlobeNewswire) +5.53%
Jan-22-24 07:25AM	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones (GlobeNewswire)
Dec-21-23 12:30AM	Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer (GlobeNewswire)
Dec-04-23 04:35PM	Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress (GlobeNewswire) +153.01% -22.86%
02:15PM	Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today? (InvestorPlace)
07:25AM	Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease (GlobeNewswire)
Nov-27-23 07:25AM	Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy (GlobeNewswire) -6.49%
Nov-16-23 07:25AM	Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 (GlobeNewswire)
Nov-08-23 07:25AM	Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +12.77%
Oct-30-23 07:25AM	Appendix 4C Q1 FY24 Quarterly Cash Flow Report (GlobeNewswire) -5.98%
Aug-31-23 07:25AM	Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder (GlobeNewswire)
Aug-23-23 07:25AM	Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinsons and Alzheimers (GlobeNewswire)
Aug-22-23 07:25AM	Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinsons Disease and Movement Disorders (GlobeNewswire)
Aug-15-23 07:25AM	Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund (GlobeNewswire)
Jul-31-23 07:52AM	Appendix 4C Q4 FY23 Quarterly Cash Flow Report (GlobeNewswire)
Jul-26-23 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned (GlobeNewswire) +6.49%
Jun-21-23 07:25AM	Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023 (GlobeNewswire)
May-30-23 07:25AM	Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder (GlobeNewswire) +6.51%
May-19-23 07:25AM	Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023 (GlobeNewswire)
May-10-23 07:25AM	Appendix 4C Q3 FY23 Quarterly Cash Flow Report (GlobeNewswire)
07:25AM	Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Apr-26-23 07:25AM	Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology (GlobeNewswire)
Apr-04-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Mar-16-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.70%
Mar-14-23 07:25AM	Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimers Disease (GlobeNewswire) -7.14%

Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

CEODr. David A. Stamler M.D.

B.Sc.Ms. Abby Macnish Niven B.Com.

Chief Scientific Advisor and Member of Research & Development Advisory BoardDr. Rudolph Emile Tanzi Ph.D.

Chief Medical AdvisorDr. Steven D. Targum M.D.

Head of ResearchDr. Robert Cherny

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marks Peter Ashley	Director	Aug 31 '26	Buy	0.50	47,620	23,810	191,340	Sep 08 07:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHE

Alterity Therapeutics Ltd ADR

Upgrade your Finviz experience